Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05381064 |
Other study ID # |
EA-22-004 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 1, 2022 |
Est. completion date |
January 1, 2024 |
Study information
Verified date |
May 2022 |
Source |
Renmin Hospital of Wuhan University |
Contact |
Yu Honggang, Doctor |
Phone |
13871281899 |
Email |
yuhonggang[@]whu.edu.cn |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The bile duct scanning system based on deep learning can prompt endoscopists to scan standard
stations and identify bile ducts and stones in real time. The purpose of this study is to
evaluate the effectiveness and safety of the proposed deep learning-based bile duct scanning
system in improving the diagnostic accuracy of common bile duct stones and reducing the rate
of missed gallstones during bile duct scanning by novice ultrasound endoscopists in a
single-center, tandem, randomized controlled trial
Description:
The incidence of gallstones has been increasing in recent years, up to 10-15% in developed
countries, and is still increasing at a rate of 0.6% per year. It is estimated that common
bile duct stones (CBDS) are present in about 10-20% of patients with symptomatic bile duct
stones. Each year, common bile duct stones lead to acute complications such as biliary
obstruction, cholangitis and acute pancreatitis in a large number of patients, seriously
endangering their lives and health. In addition, Diagnosis Related Group (DRG) analysis shows
that each episode of common bile duct stones costs $9,000, and acute pancreatitis that
progresses from common bile duct stones can result in 275,000 hospitalizations annually,
incurring $2.6 billion in costs and imposing a significant economic and health burden on
society. Therefore, timely diagnosis of common bile duct stones and intervention for them is
crucial. Endoscopic retrograde cholangiopancreatography (ERCP) is the method of choice for
the diagnosis and treatment of CBDS, and guidelines recommend stone extraction for all
patients with CBDS who are physically fit enough to tolerate ERCP operations. However, ERCP
is a highly demanding and risky operation with the potential for serious complications such
as PEP (incidence 2.6-3.5%). How to diagnose choledocholithiasis early and accurately,
achieve timely intervention to improve prognosis, and avoid unnecessary medical operations to
reduce risks are the challenges we are currently trying to solve.
The guidelines recommend ultrasound endoscopy (EUS) or magnetic resonance
cholangiopancreatography (MRCP) to determine the presence of CBDS, depending on the local
level of care, for patients in the intermediate-risk group for CBDS and for patients in the
low-risk group whose physicians still have a high suspicion of CBDS. sensitivity. In
addition, a cost-effectiveness analysis showed that MRCP would be the preferred test when the
predicted probability of CBDS is less than 40%, while EUS is the preferred test when the
predicted probability is 40%-90%. Compared to MRCP, EUS has a wide range of applicability but
a steep learning curve. ASGE states that a minimum of 225 EUS operations are required to
qualify, while the ESGE states that a minimum of 300 operations are required. However, this
experience can only be gained at training centers that perform a large number of cases. Thus,
the training of novice physicians in resource-limited areas is a huge challenge, which leaves
a significant shortage of experienced ultrasound endoscopists with poor performance in the
actual diagnosis of common bile duct stones, greatly limiting the popularity of ultrasound
endoscopy.
The purpose of this study is to evaluate the effectiveness and safety of the proposed deep
learning-based bile duct scanning system in improving the diagnostic accuracy of common bile
duct stones and reducing the rate of missed gallstones during bile duct scanning by novice
ultrasound endoscopists through a single-center, tandem, randomized controlled trial